DENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana derivative) products, is pleased to announce that we have now received verbal confirmation that the sites of the former cancerous lesions are free of cancer cells and we are now awaiting official Physician documentation of the patient's history and biopsy reports.
Dr. Robert J. Melamede, the CEO and President of Cannabis Science Inc., stated, “The photographic documentation in our last press release, demonstrated that cannabis extracts appeared to be effective against what seems to be the patient's third incidence of basal cell carcinoma. For accuracy, it should be noted that a before treatment biopsy of the lesion on the nose was not been performed. It is obvious that there was a lesion-centered response to the application of the cannabis extract. This patient had a previous surgically removed lesion, as well as a biopsied basal cell carcinoma on the right cheek. The lesion on the cheek was also self-treated and resolved with cannabis extracts over a half year ago. This deeper cheek lesion did not visually respond like the lesion on the nose, hence there is no photographic record.”
Cannabis Science is committed to making cannabis-based medicines available to the public as rapidly as possible. The Company is taking multiple approaches to accomplishing this aim in the United States. The science of cannabinoids has exploded over the past decade, laying the scientific foundation for the many medicinal uses of this unique plant. Cannabinoids are a class of biologically active compounds produced by all vertebrates, the Cannabis plant, and more recently patentable synthetic compounds produced by chemists. In fact, modern peer-reviewed science supports the many historical uses that were discovered over thousands of years of medicinal use by herbalists.
Dr. Melamede concludes with, “More importantly, before and after treatment biopsies were performed and again we are very happy to report that the sites of the former lesions have both been verbally confirmed by a physician to be free of cancer cells and we await the formal written documentation. The lag of the United States federal government, and most governments world wide, to embrace modern cannabis science has forced people to turn to their states in an effort to make this unique medicine legally available to suffering patients. Because of the extremely low toxicity of cannabinoids, and generally high safety profile of these compounds, medical marijuana patients have become patient scientists. Rick Simpson is the leading patient scientist to have explored the use of cannabis extracts to treat cancers. It was because of his pioneering work, and anecdotal reports from patient scientists from all over the world, that Cannabis Science has been working with and educating patients.”
Please visit www.cannabisscience.com to view the “Breaking News” of the successful results and images of the self-administered cancer treatments. Cannabis Science will hold a press conference once the official documented Physician reports are received to formally announce its cancer formulation progress and future plans for cancer treatments. Brand names for new cancer treatment drugs are currently being vetted through the company attorney for future commercial use.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.